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This manual was first developed in 1996 to provide general guidance to state and local health 
department personnel who are involved in surveillance activities for vaccine-preventable diseases. 
This manual answers commonly asked questions regarding the surveillance and reporting of 
vaccine-preventable diseases and provides information on enhancing existing surveillance systems.
Several reference documents, tables, and worksheets have been included in this manual for your 
convenience and information. The worksheets in this manual are in the public domain and may be 
copied and distributed for use in public health surveillance activities.
Please forward any suggestions and comments regarding this manual to:
Surveillance Officer 
National Center for Immunization and Respiratory Diseases 
Centers for Disease Control and Prevention 
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Definitions of Terms
Attenuated virus A strain of virus whose virulence has been lowered by physical or chemical processes or by repeated passage through the cells of another species. 
Breakthrough The appearance of clinical disease in an individual who has previously been vaccinated against the agent causing the disease.
Clinically compatible case
A case featuring a clinical syndrome generally compatible with the disease, 
but for which specific clinical criteria may not have been met unless they are 
noted in the case classification. 
Confirmed case A case that is classified as confirmed for reporting purposes. 
Contraindication
A characteristic or attribute of an individual that may be temporary or 
permanent that prohibits the administration of a drug, vaccine, or other 
therapeutic intervention. 
Encephalitis
An inflammatory condition of brain tissue caused by a variety of infectious 
and non-infectious diseases. In varicella, influenza, and measles, this is 
sometimes referred to as post-infectious encephalitis. 
Epidemiologically linked case
A case in which the patient has or has had contact with one or more 
persons who have or have had the disease, and transmission of the agent 
by the usual modes of transmission is plausible. In general, a case may be 
considered epidemiologically linked to a laboratory-confirmed case if at least 
one case in the chain of transmission is laboratory confirmed. 
Erythema Redness (or inflammation) of the skin or mucous membranes that is the result of dilation and congestion of superficial capillaries. 
Exanthem
A skin eruption or rash that may have specific diagnostic features of an 
infectious disease. Chickenpox, measles, roseola infantum, rubella, and 
smallpox are usually characterized by a particular type of exanthem. 
Immunocompromised
A state in which an individual has either a decreased or absent ability to 
mount an antibody and/or cell-mediated immune response to infectious 
agents. 
Incubation period The period of time from exposure to an infecting agent to the onset of symptoms of disease. 
Laboratory confirmed case 
A case that is confirmed by one or more of the laboratory methods listed 
in the case definition under “Laboratory criteria.” Although other laboratory 
methods may be used in clinical diagnosis, only those listed are accepted for 
laboratory confirmation for reporting purposes. 
Line listing 
A tool used during epidemiologic investigations to allow investigators to 
record case information and to review and follow up case reports or conduct 
data analysis. 
Meets the clinical case definition
Meets precisely the clinical case definition. Although in clinical practice the 
diagnosis may be made with the use of other criteria, for reporting purposes 
the stated criteria must be met. 
Primary vaccine failure
The absence of seroconversion after vaccination. This is manifest as the 
occurrence of disease in a vaccinated individual in which the disease 
occurrence closely resembles that found in natural infection with wild-type 
virus, i.e., more commonly moderate or severe disease. 
Probable case A case that is classified as probable for reporting purposes. 
Secondary vaccine failure Loss of immunity acquired after vaccination. 
Sentinel event A preventable disease, disability, or untimely death that serves as a warning signal of a possible underlying problem. 
Definitions of Terms  ix
Sentinel surveillance
Activities focused on monitoring key health indicators in the general 
population or in special populations. The primary intent is to obtain timely 
information needed for public health or medical action in a relatively 
inexpensive manner rather than to derive precise estimates of prevalence or 
incidence in the general population. 
Supportive laboratory results Specified laboratory results consistent with the diagnosis but not meeting the criteria for laboratory confirmation. 
Susceptible Being sensitive to effects of an infectious disease, allergen, or other pathogenic agent; lacking immunity or resistance. 
Thermolability A characteristic of vaccines that cause them to lose potency when stored or held at temperatures other than that recommended by the manufacturer. 
Vaccine coverage The proportion or percentage of persons that have received a vaccine among all individuals in a particular group who are eligible to receive the vaccine. 
Vaccine effectiveness The ability of a vaccine to provide protection against disease when used under field conditions (e.g., use of the vaccine in routine practice).
Vaccine efficacy The ability of a vaccine to provide protection against disease under ideal circumstances (e.g., during a clinical trial).
